Category : Healthcare and Pharmaceuticals | Published at : January-2020 | Delivery Format : PDF | Status: Published | Pages : 190
The global cancer gene therapy market size is expected to reach around US$ 3.2 Bn by 2026 and growing at a CAGR of around 29.7% over the forecast period 2019 to 2026.
Cancer has been increasing widely across the globe and can be medicated by somatic aberration in the host genome. The researchers and scientist discovered the therapy in genetic manipulation to improve cancer regression and find a potential cure for the disease. The cancer gene therapy includes transferring of genetic material into a host cell through Ex-vivo and In-vivo and manipulation of the tumor microenvironment, to reduce tumor vasculature. The main function of cancer gene therapy is regeneration or replacement of mutated genes with healthy genes. Based on product, different types of cancer gene therapy products such as viral vectors, non-viral vectors, and others are used. According to WHO, there are about 18 million cancer cases in 2018, in which 9.5 million cases were in men and 8.5 million in women and estimated 9.6 million deaths in 2018.
Market Dynamics
The growth of the cancer gene therapy market is primarily driven by the rising prevalence of cancer, increase in geriatric population across the globe, and technological advancements in cancer gene therapy. Furthermore, increase in demand and preference for non-invasive treatment and expanding base of cancer patients worldwide, is estimated to boost the market growth. Moreover, changing lifestyles of consumers across developed countries, growing pharmaceutical and medical industry, technological advancement and increase in the number of applications are expected to create opportunities for the manufacturers in the global market over the forecast period. However, high treatment costs and low purchasing power of consumers are expected to hamper the growth of the global cancer gene therapy market in the coming years.
By type, ex-vivo cancer gene therapy segment dominated the cancer gene therapy market
The ex-vivo cancer gene therapy segment accounted for approximately 54% of the share in the global cancer gene therapy market in 2018. Increase in demand for treatment in blood cancer, creating and modification of cells outside body to increase the stability of treatment, and rising incidences of various diseases is further expected to raise segment over the forecast period.
By end-use, hospitals segment dominated the cancer gene therapy market
The hospitals segment accounted for approximately 41% of the share in the global cancer gene therapy market in 2018. Growing demand for multi-specialty treatment and devices and cataract procedures and growing consumer preference towards technology advanced surgical procedures performed in hospitals is further expected to raise segment over the forecast period. Owing to its growing number of surgery, growing number of devices requirement in hospitals, and supportive government initiatives for cancer gene therapy in hospitals further grows the demand for cancer gene therapy in hospitals applications during the forecast period.
By product, non-viral vectors segment dominated the cancer gene therapy market
The non-viral vectors segment accounted for approximately 44% of the share in the global cancer gene therapy market in 2018. The non-viral vectors have low toxicity and immunogenicity that reduces the risks of infections and allergies in patients in treatment of cancer. Geriatric population across the globe and growing incidence of cataract, and rising demand for safe surgery is further expected to raise segment over the forecast period.
The market research study on “Cancer Gene Therapy Market– Global Industry Analysis, Market Size, Opportunities and Forecast, 2019 – 2026”, offers a detailed insight into the global cancer gene therapy market entailing insights on its different market segments. Market dynamics with drivers, restraints, and opportunities with their impact are provided in the report. The report provides insights into the global cancer gene therapy market, its product type, product, end-use, and major geographic regions. The report covers basic development policies and layouts of technology development processes. Secondly, the report covers global cancer gene therapy market size, and segment markets by type, product, end-use, and geography along with the information on companies operating in the market. The cancer gene therapy market analysis is provided for major regional markets including North America, Europe, Asia Pacific, Latin America and Middle East and Africa. For each region, the market size for different segments has been covered under the scope of the report.
In 2018, North America dominated the regional market with a maximum market share
North America accounted for the high market share of the cancer gene therapy market and the region is also expected to maintain its dominance over the forecast period. The region is experiencing the maximum growth owing to the rapid consumption of cancer gene therapy in various end user applications, presence of cancer gene therapy companies, favorable reimbursement policies, and rapidly growing geriatric population. Highly efficient reimbursement structure and developed healthcare infrastructure in the North America region is one of the key factors driving the consumption of cancer gene therapy in this region. Moreover, highly skilled neurosurgeons, growing number of hospitals and research centers in key countries such as US and Canada are also propelling the growth of cancer gene therapy in the North America region. Europe is followed by the North America region in the cancer gene therapy market.
Asia-Pacific is expected to hold the highest CAGR in the global market during the forecast period. The growing prevalence of cancer, increase in innovation and development in cancer gene therapy, and growing geriatric populations, are expected to enhance the market growth in the global cancer gene therapy market during the forecast.
The players profiled in the report include Vigene Biosciences, Sirion Biotech, bluebird bio, Cellectis, and Ziopharm, Cobra, Finvector, Sangamo Therapists Inc., Novartis AG, Sarepta Therapeutics, and Caribou among others. The companies are involved in mergers and acquisitions and new product development for expanding their market share and also for gaining competitive advantages over its competitors.
Market Segmentation
Market By Type
- Ex-vivo
- In-vivo
Market By Product
- Viral Vectors
- Non-viral Vectors
- Others
Market By End-use
- Biopharma companies
- Research Institutes
- Others
Market By Geography
- North America
- U.S.
- Canada
- Europe
- UK
- Germany
- France
- Spain
- Rest of Europe
- Asia-Pacific
- China
- Japan
- India
- Australia
- South Korea
- Rest of Asia-Pacific
- Latin America
- Brazil
- Mexico
- Rest of Latin America
- Middle East & Africa
- GCC
- South Africa
- Rest of Middle East & Africa
Frequently Asked Questions
The main function of cancer gene therapy is regeneration or replacement of mutated genes with healthy genes.
Factors such as rising prevalence of cancer, increase in geriatric population across the globe restrain the cancer gene therapy market growth.
Acumen Research and Consulting says that, the cancer gene therapy market value is anticipated to be worth around US$ 3.2 million in 2026.
The cancer gene therapy market is anticipated to grow over 29.7% CAGR during the forecast period 2019 to 2026.
North America held maximum share in 2018 for cancer gene therapy market.
Asia Pacific is projected to grow at a fast pace during forecast period in the cancer gene therapy market.
Vigene Biosciences, Sirion Biotech, bluebird bio, Cellectis, and Ziopharm, Cobra, Finvector, Sangamo Therapists Inc., Novartis AG, Sarepta Therapeutics are the top players operating in the cancer gene therapy market.
